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INTRODUCTION
Tumour lysis syndrome (TLS) is a serious complication 
of cancer treatment. Acute TLS, which is a clinical picture 
with life-threatening metabolic disorders and caused by 
rapid destruction of tumour cells, occurs in haematological 
malignancies with large tumour mass (acute lymphocytic 
leukaemia, non-Hodgkin’s lymphoma) and rarely in 
solid malignancies.  Metabolic disorders are characterized 
by hyperuricaemia, acute renal failure, hyperkalaemia, 
hyperphosphataemia and hypocalcaemia.  Although TLS 
is most commonly seen in chemosensitive tumours in 
the first days of chemotherapy or radiotherapy, it may 
rarely develop spontaneously in the tumours with high 
proliferation.
Acute spontaneous tumour lysis before chemotherapy is 
rarely encountered in acute leukaemia and high-grade 
non-Hodgkin’s lymphoma which shows high-grade 
mitotic activity [1-3].  There is a positive correlation of the 
development of acute renal failure (ARF) with tumor size, 
and elevated serum LDH and uric acid levels [2].
CASE REPORT
An 80-year-old male patient was admitted to the general 
internal medicine clinic due to a swelling in his neck.  It 
was found out that the swelling in his neck had been there 
for about 6 months, he had lost 7-8 kg within the last 6 
months, and his night sweats had increased for the last one 
month.  Bilaterally palpable cervical and supraclavicular 
lymph nodes were detected on physical examination. 
His past medical history revealed that the patient 







). He did not receive adjuvant 
chemotherapy and radiotherapy since it was early stage 
disease. The supraclavicular lymph node of the patient 
who was hospitalized in our clinic with the pre-diagnosis 
of lymphoma was excised. Histopathological diagnosis was 
CD20 positive diffuse large cell non-Hodgkin lymphoma – 
a form of high-grade lymphoma. Staging positron emission 
tomography (FDG-18 PET / CT) showed multiple lymph 
nodes in the supradiaphragmatic and infradiaphragmatic 
lymphatic stations with conglomerated-mass appearance 
and intense / hyperintense metabolic changes, and also 
in the spleen, and foci in the left proximal humerus, left 
eighth costa and left  part of sacrum in the skeleton. 
Spontaneous tumour lysis syndrome was suspected in 
the patient who had hyperuricaemia, azotaemia, and 
hyperphosphataemia in blood and who developed oliguric 
acute renal failure rapidly on the third day of admission. 
(Table 1) Intravenous fluid replacement, urine alkalization, 
forced diuresis and allopurinol therapy were initiated 
immediately.  Despite the treatment, severe metabolic 
acidosis developed and the patient received hemodialysis 
treatment. However, the clinical picture of acute renal 
failure worsened and mental confusion developed rapidly, 
and the patient died in the intensive care unit on the fifth 
day of treatment.
DISCUSSION
In haematologic and solid tumours, metabolic disorders 
such as hyperuricaemia and hyperuricaemic renal failure, 
hyperkalaemia, hyperphosphataemia with hypocalcaemia 
Metabolic disorders such as hyperuricaemia and hyperuricaemic renal failure, hyperkalaemia and hyperphosphataemia 
in hematological malignancies with high tumour burden and high turnover and rarely in solid malignancies are defined 
as acute tumour lysis syndrome.  It frequently occurs after treatment (chemotherapy / radiotherapy) and rarely occurs 
before treatment. In this case, it is called spontaneous acute tumour lysis syndrome. We aimed to remind this rare clinical 
entity with high mortality risk by presenting a patient with non-Hodgkin’s lymphoma and acute spontaneous tumour lysis 
syndrome.
Key Words: Acute spontaneous tumour lysis syndrome, non-Hodgkin lymphoma, renal failure
Acute spontaneous tumour lysis syndrome in a 
patient with non-Hodgkin’s lymphoma: a rare case
report 
Selçuk Ergen
Department of Medical Oncology, Erzurum Education and Research Hospital, Erzurum, Turkey
Correspondence: Selçuk Ergen: dr.selcukergn@hotmail.com
Submitted: December 2017    Accepted: April 2018     Published:  August 2018
CASE REPORT
69 South Sudan Medical Journal  Vol 11. No 3. August 2018
are defined as acute tumour lysis syndrome. Spontaneous 
occurrence of this syndrome before treatment is rarely 
observed while it frequently occurs after treatment. 
Known risk factors for tumor lysis syndrome include 
elevated LDH ( lactic dehydrogenase) level which is twice 
more than normal, solid tumors with high proliferation 
ability, total tumour volume larger than 10 cm, high 
tumour burden sensitive to chemotherapy or radiotherapy 
and high white count acute leukaemia (WBC>100,000 
cell/µl). 
Spontaneous acute tumour lysis syndrome developing 
without any precipitating factor was reported in the 
literature for Burkitt’s lymphoma [3], diffuse large B cell 
lymphoma and Richter’s syndrome [4], anaplastic large 
T-cell lymphoma [5], acute myeloid leukaemia [6] acute 
lymphoblastic leukaemia [7], metastatic germ cell tumour 
[8], lung adenocarcinoma [9], squamous cell carcinoma [10], 
breast cancer [11], gastric cancer [12], cholangiocarcinoma 
[13], myelofibrosis [14], multiple myeloma [15] and 
myelodysplastic syndrome [16].
What is laid emphasis on the pathogenesis of tumour 
lysis syndrome is the release of intracellular metabolites 
(nucleic acid, potassium, phosphorus, uric acid) and 
cytokines after rapid tumour necrosis. These metabolites 
cause hyperuricaemia, hyperphosphataemia and 
hyperkalaemia in blood.  The precipitation of calcium-
phosphate crystals and uric acid crystals, which develop 
secondarily to hyperphosphataemia, in the renal tubules 
causes obstructive nephropathy and renal failure. This 
metabolic state may cause cardiac dysrhythmias, mental 
confusion, seizure and sudden death other than acute 
renal failure. Meanwhile, released cytokines may cause 
systemic inflammation and multiple organ failure. 
Appropriate intravenous fluid replacement, urine 
alkalization, correction of metabolic acidosis and electrolyte 
imbalance, and decreasing uric acid synthesis form the 
basis of treatment in the patients with acute tumor lysis. 
Also, rasburicase, a recombinant urate oxidase inhibitor, 
was shown to reduce mortality and morbidity in acute 
tumour lysis [17].  Haemodialysis can be performed in the 
patients with life-threatening hyperkalaemia or persistent 
oliguria despite aggressive intravenous hydration.
CONCLUSION
Acute spontaneous tumor lysis syndrome is a rare 
metabolic emergency with high mortality risk.  For early 
recognition and prevention of this syndrome, it should 
be kept in mind that it may occur in the patients with 
high risk before chemotherapy treatment and may have a 
mortal course.
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Parameters 1st day 3th day 5th day
Urea (mg/dl)     83   112   182 
Creatinine(mg/dl)     1   1.6   3.1 
Uric acid (mg/dl)     6.5   8.3   9.3 
Potassium (mEq/L)     4.9 4.8   5.8 
Calcium (mg/dl)     9.8  10.3  10.2 
Phosphorus(mg/dl)     3.5   5.4   6.1 
LDH(IU/L)    737 1100  1831 
ALP (IU/L)    250   281   584 
Haemoglobin (gr/dl)    8.3  10.7  10.5 
Haematocrit (%)   26.4  32.8  32.2 
WBC (cell/µl)  12100 16100  18600 
Platelets (cell/µl) 121000 111000 53000
Table 1. Biochemical and hematological parameters of our 
patient 
LDH : Lactic dehydrogenase
ALP : Alkaline phosphatase
WBC : White blood cells
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